Nicholas Hunt, MD
Nephrology · Boise, IDNPI 1780621771
Payments from drug & device makers
What this record shows
6 manufacturers reported payments, led by Genentech, Inc. at 41.7% of the total. 2025 is the largest year on record at $147, 4.0 times the $37 reported in 2019. That places this record below the midpoint for nephrology clinicians in ID, where the typical reported total is $347.
Across 18 payments — averaging $14.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$107
- Novo Nordisk$40
- AstraZeneca$33
- Travere Therapeutics, Inc.$32
- Genentech USA, Inc.$24
- Vifor Pharma, Inc.$21
What the payments were for
- Food & beverage$11846%
- Education$13854%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 2 | $107 |
| Novo Nordisk | 2 | $40 |
| AstraZeneca | 2 | $33 |
| Travere Therapeutics, Inc. | 10 | $32 |
| Genentech USA, Inc. | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $21 |
How this compares
$256 in reported general payments places this provider in the 45th percentile of 30 nephrology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 184 | $153,901 |
| FarxigaDapagliflozin Propanediol | 164 | $153,646 |
| EliquisApixaban | 52 | $45,931 |
| RenvelaSevelamer Carbonate | 18 | $27,184 |
| Sevelamer Carbonate | 76 | $18,093 |
| LokelmaSodium Zirconium Cyclosilicate | 27 | $15,190 |
| Everolimus | 15 | $13,200 |
| Colchicine | 19 | $4,814 |
| DapagliflozinDapagliflozin Propanediol | 11 | $4,619 |
| Midodrine Hcl | 28 | $4,099 |
| Bumetanide | 35 | $2,659 |
| Mycophenolate Mofetil | 22 | $2,354 |
| Potassium Chloride | 39 | $1,930 |
| Losartan Potassium | 161 | $1,420 |
| Calcium Acetate | 16 | $1,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $33 | $168,837191 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 30 nephrology providers in Idaho.
Other nephrology in Boise
- Micheal AdcoxBoise$221
- Thomas PintarBoise$164
- Arnold SilvaMeridian$626K
- Liang WuMeridian$386K
- Mary DittrichMeridian$7K
- Shaun JoshiHayden$5K
- Heidi JoistNampa$4K
- Naeem RahimChubbuck$696
- Kevin MitchellMeridian$679
- Ajith KumarLewiston$672
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.